Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 11, 2012, Pages 1564-1584

  Richie, Thomas L ^a   Charoenvit, Yupin ^a   Wang, Ruobing ^a,b   Epstein, Judith E ^a   Hedstrom, Richard C ^a   Kumar, Sanjai ^a,b   Luke, Thomas C ^a   Freilich, Daniel A ^a   Aguiar, Joao C ^c   Sacci, John B ^a,b   Sedegah, Martha ^a   Nosek, Ronald A ^a   De La Vega, Patricia ^a,b   Berzins, Mara P ^a,b   Majam, Victoria F ^a,b   Abot, Esteban N ^a,b   Ganeshan, Harini ^a,b   Richie, Nancy O ^a,b   Banania, Jo Glenna ^a,b   Baraceros, Maria Fe B ^a,b   Geter, Tanya G ^a,b   Mere, Robin ^d   Bebris, Lolita ^a,b   Limbach, Keith ^a,b   Hickey, Bradley W ^a   Lanar, David E ^e   Ng, Jennifer ^f   Shi, Meng ^e   Hobart, Peter M ^d   Norman, Jon A ^d   Soisson, Lorraine A ^g   Hollingdale, Michael R ^a,b   Rogers, William O ^a   Doolan, Denise L ^a   Hoffman, Stephen L ^a,h   more..

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

^d VICAL INC   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f CW Bill Young Department of Defense Marrow Donor Program   (United States)

^g UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^h SANARIA INC   (United States)

Author keywords

Clinical trials; Controlled human malaria infection; DNA vaccine; GM CSF; Malaria; Malaria challenge; Malaria vaccine; Plasmodium falciparum; Vaccine safety

Indexed keywords

ANTIBODY; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EXPORTED PROTEIN 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MUSTDO5 VACCINE; PARASITE ANTIGEN; PROTEIN SSP; PROTEIN TRAP; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARM MOVEMENT; ARTHRALGIA; ARTICLE; CELLULAR IMMUNITY; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FIRST IN HUMAN STUDY; HUMAN; IMMUNOGENICITY; INJECTION SITE ECCHYMOSIS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSECT BITE; JET INJECTOR; LABORATORY TEST; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALAISE; MALARIA FALCIPARUM; MALE; MYALGIA; NAUSEA; NECK PAIN; OPEN STUDY; PLASMODIUM FALCIPARUM; PROTECTION; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SLEEP DISORDERED BREATHING; VIRUS RECOMBINANT; VOMITING; WEIGHT GAIN;

EID: 84869767669     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22129     Document Type: Article

References (96)

1. WHO. World Malaria Report. 2011.
2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413-31; PMID:22305225; http://dx.doi.org/10.1016/S0140-6736(12)60034- 8.
3. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-75; PMID:22007715; http://dx.doi.org/10.1056/NEJMoa1102287.
4. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 2009; 8:312; PMID:20042088; http://dx.doi.org/10.1186/1475-2875-8-312.
5. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24:397-401; PMID:808142.
6. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974; 68:258- 9; PMID:4608063; http://dx.doi.org/10.1016/0035-9203(74)90129-1.
7. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64; PMID:11930326; http://dx.doi.org/10.1086/339409.
8. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77; PMID:19641203; http://dx.doi.org/10.1056/NEJMoa0805832.
9. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770-6; PMID:21514658; http://dx.doi.org/10.1016/S0140-6736(11)60360-7.
10. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011; 334:475-80; PMID:21903775; http://dx.doi.org/10.1126/ science.1211548.
11. Hoffman SL, Weiss W, Mellouk S, Sedegah M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett 1990; 25:33- 8; PMID:2283160; http://dx.doi.org/10.1016/0165-2478(90)90087-7.
12. Weiss WR, Mellouk S, Houghten RA, Sedegah M, Kumar S, Good MF, et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 1990; 171:763-73; PMID:1689762; http://dx.doi.org/10.1084/jem.171.3.763.
13. Hoffman SL, Sedegah M, Hedstrom RC. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine 1994; 12:1529-33; PMID:7879419; http://dx.doi.org/10.1016/0264- 410X(94)90078-7.
14. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91:9866-70; PMID:7937907; http://dx.doi.org/10.1073/pnas.91. 21.9866.
15. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95:7648-53; PMID:9636204; http://dx.doi.org/10.1073/pnas.95.13.7648.
16. Rogers WO, Weiss WR, Kumar A, Aguiar JC, Tine JA, Gwadz R, et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 2002; 70:4329- 35; PMID:12117942; http://dx.doi.org/10.1128/IAI.70.8.4329- 4335.2002.
17. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:5933-42; PMID:16988273; http://dx.doi.org/10.1128/IAI.00590-06.
18. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:4836-41; PMID:15781866; http://dx.doi.org/10.1073/ pnas.0406381102.
19. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS ONE 2011; 6:e24586; PMID:22003383; http://dx.doi.org/10.1371/journal.pone.0024586.
20. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 2011; 6:e25868; PMID:22003411; http://dx.doi.org/10.1371/journal.pone.0025868.
21. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38:732-41; PMID:18266272; http://dx.doi.org/10.1002/eji.200737672.
22. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78:145-53; PMID:19858306; http://dx.doi.org/10.1128/IAI.00740-09.
23. Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 67:59-68; PMID:7838184; http://dx.doi.org/10.1016/0166-6851(94)90096-5.
24. Robson KJ, Hall JR, Jennings MW, Harris TJ, Marsh K, Newbold CI, et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988; 335:79-82; PMID:3045563; http://dx.doi.org/10.1038/335079a0.
25. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, et al. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci USA 1992; 89:9176-80; PMID:1409621; http://dx.doi.org/10.1073/ pnas.89.19.9176.
26. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 2001; 31:753- 62; PMID:11403765; http://dx.doi.org/10.1016/S0020-7519(01)00184-9.
27. Kumar S, Epstein JE, Richie TL, Nkrumah FK, Soisson L, Carucci DJ, et al. A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol 2002; 18:129-35; PMID:11854091; http://dx.doi.org/10.1016/ S1471-4922(01)02207-3.
28. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893-901; PMID:10699338; http://dx.doi.org/10.1016/S0264-410X(99)00407- 7.
29. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needlefree jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002; 13:1551-60; PMID:12228010; http://dx.doi.org/10.1089/ 10430340260201644.
30. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-80; PMID:9774275; http://dx.doi.org/10.1126/ science.282.5388.476.
31. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 2005; 73:2863- 72; PMID:15845492; http://dx.doi.org/10.1128/IAI.73.5.2863-2872.2005.
32. Nussenzweig V, Nussenzweig RS. Circumsporozoite proteins of malaria parasites. Cell 1985; 42:401-3; PMID:2411417; http://dx.doi.org/10.1016/0092- 8674(85)90093-5.
33. Doolan DL, Hedstrom RC, Rogers WO, Charoenvit Y, Rogers M, de la Vega P, et al. Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. J Biol Chem 1996; 271:17861-8; PMID:8663412; http://dx.doi.org/10.1074/jbc.271.30.17861.
34. Zhu J, Hollingdale MR. Structure of Plasmodium falciparum liver stage antigen-1. Mol Biochem Parasitol 1991; 48:223-6; PMID:1840628; http://dx.doi.org/10.1016/0166-6851(91)90117-O.
35. Prieur E, Druilhe P. The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas. Malar J 2009; 8:247; PMID:19874576; http://dx.doi.org/10.1186/1475-2875- 8-247.
36. Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, et al. A plasmid encoding murine granulocyte- macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161:2325-32; PMID:9725227.
37. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-44; PMID:18551128; http://dx.doi.org/10.1038/ nri2356.
38. Mirza S, Walker A, Chen J, Murphy JM, Young IG. The Ig-like domain of human GM-CSF receptor alpha plays a critical role in cytokine binding and receptor activation. Biochem J 2010; 426:307- 17; PMID:20078425; http://dx.doi.org/10.1042/BJ20091745.
39. Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001; 8:1011-23; PMID:11438836; http://dx.doi.org/10.1038/sj.gt.3301491.
40. Chen Y, Webster RG, Woodland DL. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J Immunol 1998; 160:2425-32; PMID:9498786.
41. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986; 35:66-8; PMID:3511753.
42. Sinden RE. A biologist's perspective on malaria vaccine development. Hum Vaccin 2010; 6:3-11; PMID:19946205; http://dx.doi.org/10.4161/hv.6.1.9604.
43. Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991; 252:715-8; PMID:1827210; http://dx.doi.org/10.1126/ science.1827210.
44. Baer K, Klotz C, Kappe SH, Schnieder T, Frevert U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 2007; 3:e171; PMID:17997605; http://dx.doi.org/10.1371/journal.ppat.0030171.
45. Jiang G, Charoenvit Y, Moreno A, Baraceros MF, Banania G, Richie N, et al. Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar J 2007; 6:135; PMID:17925026; http://dx.doi.org/10.1186/1475-2875-6-135.
46. Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE 2009; 4:e6559; PMID:19668343; http://dx.doi.org/10.1371/journal.pone.0006559.
47. Collins WE, Contacos PG, Jumper JR, Smith CS, Skinner JC. Studies on the exoerythrocytic stages of simian malaria. 8. Plasmodium knowlesi. J Parasitol 1973; 59:344-52; PMID:4633177; http://dx.doi.org/10.2307/3278832.
48. Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996; 183:1739-46; PMID:8666931; http://dx.doi.org/10.1084/ jem.183.4.1739.
49. Hedstrom RC, Doolan DL, Wang R, Kumar A, Sacci JB Jr., Gardner MJ, et al. In vitro expression and in vivo immunogenicity of Plasmodium falciparum preerythrocytic stage DNA vaccines. Int J Mol Med 1998; 2:29-38; PMID:9854139.
50. Sedegah M, Charoenvit Y, Minh L, Belmonte M, Majam VF, Abot S, et al. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 2004; 11:448-56; PMID:14973538; http://dx.doi.org/10.1038/sj.gt.3302139.
51. Bacon DJ, Sedegah M. Reduced production of RNA transcripts from individual DNA plasmids given in a multivalent DNA vaccine formula. Hum Vaccin 2007; 3:48-53; PMID:17312401; http://dx.doi.org/10.4161/hv.3.2.3833.
52. Robertson JS. Safety considerations for nucleic acid vaccines. Vaccine 1994; 12:1526-8; PMID:7879418; http://dx.doi.org/10.1016/0264-410X(94)90077-9.
53. Chen TT, Levy R. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GMCSF fusion protein. J Immunol 1995; 154:3105-17; PMID:7897201.
54. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006; 38:623-7; PMID:16679975; http://dx.doi.org/10.1249/01.mss. 0000210192.49210.fc.
55. Kenney K, Landau ME, Gonzalez RS, Hundertmark J, O'Brien K, Campbell WW. Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysis. Muscle Nerve 2012; 45:356-62; PMID:22334169; http://dx.doi.org/10.1002/mus.22317.
56. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24:4554-61; PMID:16150517; http://dx.doi.org/10. 1016/j.vaccine.2005.08.048.
57. Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, et al.; NIAID HIV Vaccine Trials Network. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol 2012; 19:649-58; PMID:22398243; http://dx.doi.org/10.1128/CVI.00038-12.
58. Narum DL, Kumar S, Rogers WO, Fuhrmann SR, Liang H, Oakley M, et al. Codon optimization of gene fragments encoding Plasmodium falciparum merozoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 2001; 69:7250-3; PMID:11705894; http://dx.doi.org/10.1128/IAI.69. 12.7250-7253.2001.
59. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE 2011; 6:e19252; PMID:21603651; http://dx.doi.org/10.1371/journal.pone.0019252.
60. Sedegah M, Weiss W, Sacci JB Jr., Charoenvit Y, Hedstrom R, Gowda K, et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000; 164:5905-12; PMID:10820272.
61. Kumaratilake LM, Ferrante A, Jaeger T, Rzepczyk C. GM-CSF-induced priming of human neutrophils for enhanced phagocytosis and killing of asexual blood stages of Plasmodium falciparum: synergistic effects of GM-CSF and TNF. Parasite Immunol 1996; 18:115-23; PMID:9223165; http://dx.doi.org/10.1046/j.1365-3024. 1996.d01-64.x.
62. Singh PP, Singh S. Protection of mice from malaria after co-administration of recombinant mouse granulocyte- macrophage colony- stimulating factor and methionine-enkephalin. Eur Cytokine Netw 2001; 12:528-36; PMID:11566634.
63. Schneider J, Langermans JA, Gilbert SC, Blanchard TJ, Twigg S, Naitza S, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001; 19:4595-602; PMID:11535306; http://dx.doi.org/10.1016/S0264-410X(01)00260-2.
64. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, et al. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000; 165:3772-81; PMID:11034382.
65. Sedegah M, Brice GT, Rogers WO, Doolan DL, Charoenvit Y, Jones TR, et al. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun 2002; 70:3493-9; PMID:12065488; http://dx.doi.org/10. 1128/IAI.70.7.3493-3499.2002.
66. Sedegah M, Belmonte M, Epstein JE, Siegrist CA, Weiss WR, Jones TR, et al. Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J Immunol 2003; 171:3148-53; PMID:12960342.
67. Kumar S, Miller LH, Quakyi IA, Keister DB, Houghten RA, Maloy WL, et al. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 1988; 334:258-60; PMID:2456467; http://dx.doi.org/10.1038/ 334258a0.
68. Sakai T, Horii T, Hisaeda H, Zhang M, Ishii K, Nakano Y, et al. DNA immunization with Plasmodium falciparum serine repeat antigen: regulation of humoral immune response by coinoculation of cytokine expression plasmid. Parasitol Int 1999; 48:27-33; PMID:11269323; http://dx.doi.org/10.1016/S1383- 5769(98)00036-1.
69. Sanchez GI, Sedegah M, Rogers WO, Jones TR, Sacci J, Witney A, et al. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infect Immun 2001; 69:3897-905; PMID:11349057; http://dx.doi.org/10.1128/IAI.69.6.3897-3905.2001.
70. Li N, Yu YZ, Yu WY, Sun ZW. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol Immunotoxicol 2011; 33:211-9; PMID:21284488; http://dx.doi.org/10.3109/08923971003782327.
71. Bråve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005; 12:1197-205; PMID:16112909; http://dx.doi.org/10.1016/j.ymthe.2005.06.473.
72. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204:164-73; PMID:21628671; http://dx.doi.org/10. 1093/infdis/jir199.
73. Sedegah M, Charoenvit Y, Aguiar J, Sacci J, Hedstrom R, Kumar S, et al. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun 2004; 5:553-61; PMID:15318164; http://dx.doi.org/10.1038/sj.gene.6364125.
74. Rodríguez AM, Pascutti MF, Maeto C, Falivene J, Holgado MP, Turk G, et al. IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12-BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS ONE 2012; 7:e37801; PMID:22655069; http://dx.doi.org/10.1371/journal.pone. 0037801.
75. Dobaño C, Widera G, Rabussay D, Doolan DL. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 2007; 25:6635-45; PMID:17669562; http://dx.doi.org/10. 1016/j.vaccine.2007.06.036.
76. Wunderlich G, Moura IC, del Portillo HA. Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection. Infect Immun 2000; 68:5839- 45; PMID:10992493; http://dx.doi.org/10.1128/IAI.68.10.5839-5845.2000.
77. Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13:540-9; PMID:17255276; http://dx.doi.org/10.1158/1078-0432. CCR-06-2039.
78. Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008; 16:2022-9; PMID:18797450; http://dx.doi.org/10.1038/mt.2008.196.
79. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al. Phase I trial of "bi-shRNAi(furin)/ GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012; 20:679-86; PMID:22186789; http://dx.doi.org/10.1038/mt.2011.269.
80. Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol Lett 2002; 81:13-24; PMID:11841841; http://dx.doi.org/10.1016/S0165-2478(01)00316-9.
81. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164:3102-11; PMID:10706700.
82. Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, et al. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther 2009; 20:1143-56; PMID:19530914; http://dx.doi.org/10.1089/hum.2009.025.
83. Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, et al. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 2009; 27:4370-80; PMID:19497647; http://dx.doi.org/10.1016/j.vaccine.2009.01.137.
84. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113:5868-77; PMID:19304955; http://dx.doi.org/10.1182/blood-2008-11-190520.
85. Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, et al. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology 2009; 128(Suppl):e612-20; PMID:19740322; http://dx.doi.org/10.1111/j.1365-2567.2009. 03044.x.
86. Belisle SE, Yin J, Shedlock DJ, Dai A, Yan J, Hirao L, et al. Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS ONE 2011; 6:e19681; PMID:21701683; http://dx.doi.org/10.1371/journal.pone.0019681.
87. Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011; 29:6763-70; PMID:21195801; http://dx.doi.org/10.1016/j.vaccine.2010.12.055.
88. Institute NC. Common Toxicity Criteria Version 2.0. In: http://ctepcancergov/protocolDevelopment/electronic-applications/ctchtm; 1999.
89. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, Paul CF, et al. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 1990; 43:441-5; PMID:2240371.
90. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001; 98:10817-22; PMID:11526203; http://dx.doi. org/10.1073/pnas.181123498.
91. Aguiar JC, Hedstrom RC, Rogers WO, Charoenvit Y, Sacci JB Jr., Lanar DE, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001; 20:275-80; PMID:11567774; http://dx.doi.org/10.1016/S0264-410X(01)00273-0.
92. Szarfman A, Lyon JA, Walliker D, Quakyi I, Howard RJ, Sun S, et al. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol 1988; 10:339-51; PMID:2457864; http://dx.doi.org/10.1111/j.1365-3024.1988.tb00225.x.
93. Charoenvit Y, Majam VF, Corradin G, Sacci JB Jr., Wang R, Doolan DL, et al. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect Immun 1999; 67:5604-14; PMID:10531206.
94. Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, et al. Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar J 2011; 10:168; PMID:21689436; http://dx.doi.org/10.1186/1475-2875-10-168.
95. Doolan DL, Wizel B, Hoffman SL. Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs. Immunol Res 1996; 15:280-305; PMID:8988396; http://dx.doi.org/ 10.1007/BF02935313.
96. Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS ONE 2012; 7:e31247; PMID: 22355349.